sur PHAXIAM THERAPEUTICS (isin : FR001400K4B1)
PHAXIAM Therapeutics Enters Receivership and Delays Financial Results
PHAXIAM Therapeutics, a biopharmaceutical company listed on Euronext, announced the commencement of a judicial receivership procedure as of March 6, 2025. The decision, made by the Commercial Court of Lyon, comes amidst a challenging financial climate for biotech firms and after unsuccessful refinancing efforts. This strategic move aims to extend the company's financial runway.
The court has appointed Maître Joanna Rousselet as the judicial administrator for PHAXIAM. Despite these developments, the company plans to continue operations during the observation period and will provide regular updates.
The publication of PHAXIAM's full-year results for 2024 has been postponed from March 13 to March 27, 2025. Trading suspension remains in effect until further announcements. The company continues to offer phage-based treatments for severe infections while exploring options to sustain operations and preserve jobs.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de PHAXIAM THERAPEUTICS